Evidence map›Paper›PMID 40996108›Full record

ArticleEuropean journal of haematology2026

Toll-Like Receptor Polymorphisms Influence Graft-Versus-Host Disease and Infection Risk After Single-Unit Cord Blood Transplantation for Adults.

Takaaki Konuma, Megumi Hamatani-Asakura, Seiko Kato, Shohei Andoh, Hirona Ichimura, Junichi Kuroda, Kaori Kondo, Kazuaki Yokoyama, Maki Monna-Oiwa, Yasuhito Nannya and 1 more

Abstract read
In one paragraph

Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takaaki KonumaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1953-8463
Megumi Hamatani-AsakuraDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Seiko KatoDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shohei AndohDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hirona IchimuraDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Junichi KurodaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kaori KondoDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kazuaki YokoyamaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Maki Monna-OiwaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yasuhito NannyaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Satoshi TakahashiDivision of Clinical Precision Research Platform, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Funding

Ministry of Health, Labour and Welfare Science Research 24tk0124003h0002
6 · The paper itself

Abstract

backgroundToll-like receptors (TLRs) play a critical role in innate immunity by recognizing pathogen-associated and damage-associated molecular patterns. Genetic polymorphisms in TLR genes can modulate immune responses and have been implicated in the outcomes of allogeneic hematopoietic cell transplantation (HCT). However, their impact on clinical outcomes after single-unit cord blood transplantation (CBT) remains unclear.

methodsWe retrospectively analyzed adult patients who underwent single-unit CBT at our institution between January 2005 and March 2023 with available recipient or donor DNA samples. Genotyping of TLR2 (rs3804099), TLR3 (rs3775291), TLR5 (rs5744174), and TLR9 (rs352140) was performed. Associations between recipient and donor TLR polymorphisms and transplantation outcomes-including hematopoietic engraftment, acute and chronic graft-versus-host disease (GVHD), infectious complications, relapse, non-relapse mortality (NRM), and survival-were evaluated using univariate and multivariate analyses.

resultsDonor TLR2 rs3804099 and TLR9 rs352140 variants were associated with platelet engraftment rates. Recipient TLR3 rs3775291 TT genotype correlated with increased risk of grades II-IV acute GVHD and invasive fungal infection, while donor TLR5 rs5744174 GG/GA genotypes were linked to higher chronic GVHD incidence. Recipients with TLR9 rs352140 CC genotype exhibited higher bacterial bloodstream infection and NRM rates. No significant associations were found between TLR polymorphisms and overall or disease-free survival. Cytokine analyses revealed distinct profiles according to TLR polymorphisms, including elevated MCP-1 and IL-18 in TLR5 GG/GA donors and lower IL-8 in TLR9 CC recipients, suggesting mechanistic relevance.

conclusionsOur findings demonstrate that recipient and donor polymorphisms in TLR3, TLR5, and TLR9 genes affect GVHD development and infection risk following single-unit CBT in adults. Understanding these genetic influences may guide personalized approaches to improve CBT outcomes.

Indexed as

Cord Blood Stem Cell TransplantationGraft vs Host DiseaseInfectionsPolymorphism, Single NucleotideToll-Like ReceptorsAdolescentAdultAgedAllelesFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedRetrospective StudiesToll-Like Receptorsallogeneic hematopoietic cell transplantationcord blood transplantationgraft‐versus‐host diseaseinfectionpolymorphismtoll‐like receptor

Identifiers

PMID40996108
PMCPMC12673356

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.